CytoDyn, Inc.

Clinical trials sponsored by CytoDyn, Inc., explained in plain language.

CytoDyn, Inc. CYDY OTC

Biotechnology company developing leronlimab, a CCR5 antagonist for HIV and other conditions.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Trials to join now! 1 Not yet finished but already full! 1 Completed 4 Terminated 4

Last-Resort drug access opens for aggressive breast cancer patients

Disease control Expanded access

This program provides early access to an experimental drug called leronlimab for people with advanced triple-negative breast cancer who have run out of standard treatments. Participants must be adults with stage IIIB or IV cancer that has worsened despite prior therapy. The goal …

Sponsor: CytoDyn, Inc. • Aim: Disease control

Last updated Jun 27, 2026 12:25 UTC

CytoDyn, Inc.

Last-Resort drug access opens for aggressive breast cancer patients